



Annual Report

Dear Friends and Colleagues,

As I reflect upon the Washington Vaccine Association’s (WVA) twelfth full year in operation, I am pleased with our internal growth and the stability in vaccine funding that we have achieved with the help of our many stakeholders, including the Washington State Department of Health (DOH), health insurers, third-party administrators, and enrolled providers.

The WVA’s purpose and instrumental role in supporting the state’s universal purchase of childhood vaccines ensures that all children have equal access to vaccines, regardless of their insurance status. Washington’s unique childhood vaccination program will be even more critical as the federal government discontinues its purchase of COVID-19 vaccines – and the WVA will be ready to address the issues posed in partnership with our community and key stakeholders.

I am proud to announce that once again the WVA has had a successful year. The Board voted again to hold vaccine assessment costs the same year over year, allowing for fewer provider changes and greater price stability for payers, saving on total healthcare costs. The WVA’s careful fiscal planning and well-honed financial forecasting has enabled the WVA to absorb vaccine price increases and hold the vaccine assessment costs the same for three years in a row.

Furthermore, the WVA continues to build upon existing resources this past year:

- we revised and republished payer billing and provider compliance guides with the goal of reducing common dosage-based assessment errors;
- we coordinated efforts with the WA DOH to host provider training webinars and established new ways to support the onboarding of new provider practices; and
- in June 2022, the WVA Board approved the hiring of a WVA stakeholder relations liaison to aid the WVA in provider education, provider training, and support of other key stakeholders.

We are confident that these measures will improve the effectiveness of our communications and multiply our outreach efforts so that additional challenges posed by off-cycle assessment grid changes, new provider enrollment, and the future expected commercialization of COVID-19 vaccines will be well managed.

Join me in thanking our hard-working volunteer board members, WVA staff, support administrators, and the WA DOH teams who dedicate their time and resources to guide the Association.

Chad Murphy, BS, PharmD
Board Chair


Twelve Years of Stable Vaccine Funding for Washington State Children

The Washington Vaccine Association (WVA) is excited once again to share the important benefits of our state’s unique universal Childhood Vaccination Program (CVP).


- **Healthcare Savings.** The DOH’s bulk purchases of all pediatric vaccines from the Centers for Disease Control and Prevention’s (CDC) manufacturer contracts provide significant cost savings versus private market costs.
- **Stable Vaccine Supply.** Providers can focus on patient needs and have the full complement of recommended vaccines on hand to immunize children.
- **Consolidated Storage and Ordering.** Provider staff can avoid both navigating complex ordering systems and keeping separate storage inventories for vaccines based on insurance status. This allows for a blended stock of vaccines and a streamlined ordering process, supported by the CVP.
- **No Provider Financing Costs.** Instead of fronting significant dollars to keep vaccines on hand, providers receive and administer pediatric vaccines procured by the DOH and use their existing billing system to trigger the WVA’s collection of funds from health plans for privately insured children.

BY THE NUMBERS

WVA HAS FUNDED



1.54 MILLION DOSES OF VACCINE



\$29.7 MILLION

SAVED BY WVA IN VACCINE COSTS
30% below private sector costs


VACCINE PURCHASED USING WVA FUNDS



\$78.48 MILLION




985 PROVIDERS ENROLLED IN 2021

570

Total number of attendees at our new Childhood Vaccine Program training series for provider staff Nov 2021-June 2022.

Description	Tradename	WVA Assessment Amount per dose from 07/01/2021 to 06/30/2022	For Reference: CDC Private Sector Cost/Dose 04/01/2022	WVA Assessment Amount per dose as from 07/01/2022 to 06/30/2023	Percent Change 07/01/2021 to 07/01/2022
1), 2 dose schedule, live, for oral use	Rotarix®	\$97.88	\$130.82	\$97.88	0.0%
ussis vaccine and inactivated administered to children 4 through 6	Kinrix®		\$57.22		
	Quadrate™	\$41.93	\$58.36	\$41.93	0.0%



WVA BOARD OF DIRECTORS

Chad Murphy, BS, PharmD, Chair
SVP, Chief Clinical Officer,
Premera Blue Cross

Beth Harvey, MD, Vice-Chair
South Sound Pediatrics

Edgar Marcuse, MD, MPH, FPIDS, Secretary
Emeritus Professor of Pediatrics,
University of Washington

John Sobeck, MD, MBA, Treasurer
Senior Medical Director,
Regence and Asuris Health Plans
(Cambia Health Solutions)

Lydia Bartholomew, MD
CMO, Clinical Health Services West,
Aetna Life Insurance Co.

Helen Chea, MD
Pediatric Medical Director,
Molina Healthcare

John B. Dunn, MD, MPH
Medical Director for Preventative Care,
Kaiser Permanente

Jason A. Farber, Esq.
Partner, Davis Wright Tremaine LLP

Randy Parker
Salaried Administrator,
Northwest Carpenters Trusts

Michele Roberts, MPH, MCHES
Acting Assistant Secretary, Prevention
and Community Health Division,
Washington State Department of Health

WVA STAFF

Julia Walter, MA, Esq.
Executive Director

HELMES & COMPANY, INC. STAFF
Patrick B. Miller, MPH
Administrative Director

P 888.928.2224 | F 888.928.2242
info@wavaccine.org | wavaccine.org

Building Our Infrastructure to Improve Our Outreach



Over the past fiscal year, the WVA has invested in creating resources to address common stakeholder issues – further improvements are on the way! During late 2021, the WVA completed top-payer, one-on-one operational check-ins and used “lessons-learned” to create a new payer compliance check-list to aid in assessment compliance efforts. This check-list, along with a redesigned payer billing guide, was sent to all payer contacts along with the WVA’s assessment grid at the beginning of the assessment cycle.

In early 2022, the WVA expanded its focus to devote more resources to provider relations to support accurate dosage-based assessment (DBA) submissions. After partnering with and reviewing the billing practices of enrolled providers, the WVA

team formulated a strategy to address common errors causing downstream problems for payers, patients, and ultimately, the WVA. Our strategy has centered upon greater involvement in educating providers about the WVA and ensuring proper DBA training. We have also utilized payer data to identify and correct provider’s errors.

Efforts have included:

- **Developing** a provider specific compliance guide and bulletins; co-presenting with the Department of Health’s (DOH) education webinars;
- **Reinforcing** WA Childhood Vaccine Program enrollment language and patient eligibility guidelines in the DOH’s provider enrollment agreement; and
- **Billing education** to new provider enrollees.


The WVA is excited about these efforts and the resulting successes. Finally, the WVA Board recently approved the hiring of a new stakeholder relations liaison who will assist the WVA in managing provider and payer concerns. These steps are critical to improving our operational capacity and essential to supporting payers and providers alike, ensuring that our unique universal vaccine system continues to be efficient and effective.

FINANCIALS

July 1, 2021 - June 30, 2022

Childhood Vaccine Funding Sources

Estimated Total: \$175,356,933



WVA Program Expenditures

Total: \$75,784,421

